Michal Figurski
Papers
1
Total Citations
62
H-Index
1
About
Michal Figurski is a leading translational researcher whose work has significantly advanced the measurement and interpretation of Alzheimer’s disease biomarkers. His primary research focuses on the development and standardization of plasma-based assays, particularly for β-amyloid (Aβ) peptides, which are critical for early diagnosis and longitudinal monitoring of Alzheimer’s. Figurski’s most cited paper (62 citations) addresses a major bottleneck in the field: the interassay variability and inconsistency of plasma Aβ measurements across different centers. By improving the protocol for the Alzheimer's Disease Neuroimaging Initiative (ADNI), he provided a robust framework that enables reliable meta-analysis and cross-study comparisons, directly impacting how biomarkers are evaluated in large-scale clinical trials. His work has been instrumental in moving plasma Aβ from a research tool toward a clinically viable diagnostic marker. Beyond this, Figurski’s contributions to assay standardization have helped shape best practices in biomarker research, making him a key figure in the quest for accessible, non-invasive Alzheimer’s diagnostics. His meticulous approach continues to influence both academic and pharmaceutical efforts to track disease progression and therapeutic efficacy.
Research Focus
Key Achievements
Top Papers
- 1